American Headache Society® and Pfizer Announce a New Headache and Migraine Grant Program Focused on Quality Improvement
The American Headache Society (AHS), dedicated to improving the lives of those affected by migraine and other headache disorders, is pleased to announce a call for proposals as part of a Quality Improvement (QI) initiative in headache medicine. The Headache and Migraine Competitive Grant Program will fund projects that will identify and address quality gaps in headache medicine. This program is made possible by the generous support of Pfizer.
“Through this grant program, we have the unique opportunity to catalyze innovative projects to address critical gaps in headache medicine,” said Andrew Charles, MD, FAHS, President of AHS. “Funded projects will advance practical education and tools that can be shared widely with our community for maximum impact to healthcare services and the improvement of patient care.”
The AHS competitive grant program seeks to invest in projects that improve the quality of care for people with migraine and other headache disorders. Proposals of varying scope, size, and budget are encouraged to apply. Proposals should focus on major quality gaps, aiming to produce tools and information that can be widely utilized in the field. Example topics include:
- Diagnosis and management for under-represented populations
- Large-scale evaluation of “real-world” patient experiences
- Delivery of headache care in primary care settings
- Education gaps in medical school and residency training
“We are delighted to partner with Pfizer to support projects that can make a meaningful difference,” said Todd Schwedt, MD, MSCI, President-Elect of the American Headache Society and Co-Chair of its Research Committee. “This initiative not only aligns with the core mission of AHS but also underscores our commitment to advancing headache science that leads to improved healthcare outcomes.”
“Migraine is a debilitating condition that can affect every aspect of the lives of those who suffer from it. Funding quality improvements in migraine care is a crucial step toward addressing the unmet needs of the more than 40 million people in America with migraine” said Chandra Abbott, Ph.D. US Migraine Medical Affairs Lead at Pfizer. “We’re proud to partner with the American Headache Society on this important initiative aligned with our shared vision of improving the lives of people with migraine.”
The application process will involve a two-step review. Initially, a brief synopsis of the proposed project (i.e., a letter of intent (LOI)) will be reviewed. Based on this review, selected applicants will be invited to submit a full proposal. The deadline for the LOI is August 5, 2024.
For more information about this program, including detailed application guidelines and submission procedures, please visit https://americanheadachesociety.org/resources/grants/headache-migraine-competitive-grant-program.
ABOUT THE AMERICAN HEADACHE SOCIETY
The American Headache Society strives to improve the lives of people impacted by migraine and other headache disorders. The AHS is a professional society of health care providers dedicated to the study and treatment of headache and face pain. The Society’s objective is to promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Educating physicians, health professionals, and the public while encouraging scientific research are the primary functions of our Society. Learn more at AmericanHeadacheSociety.org.
ABOUT PFIZER GLOBAL MEDICAL GRANTS (GMG)
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent quality improvement initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.